1596 related articles for article (PubMed ID: 28426106)
1. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Paz-Ares L; Tan EH; O'Byrne K; Zhang L; Hirsh V; Boyer M; Yang JC; Mok T; Lee KH; Lu S; Shi Y; Lee DH; Laskin J; Kim DW; Laurie SA; Kölbeck K; Fan J; Dodd N; Märten A; Park K
Ann Oncol; 2017 Feb; 28(2):270-277. PubMed ID: 28426106
[TBL] [Abstract][Full Text] [Related]
2. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Park K; Tan EH; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; Yang JC; Lee KH; Lu S; Shi Y; Kim SW; Laskin J; Kim DW; Arvis CD; Kölbeck K; Laurie SA; Tsai CM; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L
Lancet Oncol; 2016 May; 17(5):577-89. PubMed ID: 27083334
[TBL] [Abstract][Full Text] [Related]
3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
5. Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3.
Kato T; Yoshioka H; Okamoto I; Yokoyama A; Hida T; Seto T; Kiura K; Massey D; Seki Y; Yamamoto N
Cancer Sci; 2015 Sep; 106(9):1202-11. PubMed ID: 26094656
[TBL] [Abstract][Full Text] [Related]
6. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
[TBL] [Abstract][Full Text] [Related]
7. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.
Wu YL; Sequist LV; Tan EH; Geater SL; Orlov S; Zhang L; Lee KH; Tsai CM; Kato T; Barrios CH; Schuler M; Hirsh V; Yamamoto N; O'Byrne K; Boyer M; Mok T; Peil B; Märten A; Chih-Hsin Yang J; Paz-Ares L; Park K
Clin Lung Cancer; 2018 Jul; 19(4):e465-e479. PubMed ID: 29653820
[TBL] [Abstract][Full Text] [Related]
8. Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.
Popat S; Mok T; Yang JC; Wu YL; Lungershausen J; Stammberger U; Griebsch I; Fonseca T; Paz-Ares L
Lung Cancer; 2014 Aug; 85(2):230-8. PubMed ID: 24929780
[TBL] [Abstract][Full Text] [Related]
9. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Katakami N; Atagi S; Goto K; Hida T; Horai T; Inoue A; Ichinose Y; Koboyashi K; Takeda K; Kiura K; Nishio K; Seki Y; Ebisawa R; Shahidi M; Yamamoto N
J Clin Oncol; 2013 Sep; 31(27):3335-41. PubMed ID: 23816963
[TBL] [Abstract][Full Text] [Related]
10. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].
Sárosi V; Balikó Z
Magy Onkol; 2014 Dec; 58(4):325-9. PubMed ID: 25517450
[TBL] [Abstract][Full Text] [Related]
12. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
Schuler M; Wu YL; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist LV; Massey D; Zazulina V; Yang JC
J Thorac Oncol; 2016 Mar; 11(3):380-90. PubMed ID: 26823294
[TBL] [Abstract][Full Text] [Related]
13. [Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
Vidal ÓJ
Med Clin (Barc); 2016 Apr; 146 Suppl 1():12-8. PubMed ID: 27426243
[TBL] [Abstract][Full Text] [Related]
14. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
15. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Schuler M; Yang JC; Park K; Kim JH; Bennouna J; Chen YM; Chouaid C; De Marinis F; Feng JF; Grossi F; Kim DW; Liu X; Lu S; Strausz J; Vinnyk Y; Wiewrodt R; Zhou C; Wang B; Chand VK; Planchard D;
Ann Oncol; 2016 Mar; 27(3):417-23. PubMed ID: 26646759
[TBL] [Abstract][Full Text] [Related]
16. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.
Schuler M; Tan EH; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; Yang JC; Lee KH; Lu S; Shi Y; Kim SW; Laskin J; Kim DW; Arvis CD; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1569-1579. PubMed ID: 30783814
[TBL] [Abstract][Full Text] [Related]
17. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
Yang JC; Sequist LV; Geater SL; Tsai CM; Mok TS; Schuler M; Yamamoto N; Yu CJ; Ou SH; Zhou C; Massey D; Zazulina V; Wu YL
Lancet Oncol; 2015 Jul; 16(7):830-8. PubMed ID: 26051236
[TBL] [Abstract][Full Text] [Related]
18. Real-life Effectiveness of Afatinib
Svaton M; Bratova M; Fischer O; Krejci J; Koubkova L; Cernovska M; Hrnciarik M; Zemanova M; Coupkova H; Porzer B; Dolezal D; Tuzova T; Hurdalkova K; Barinova M; Skrickova J
Anticancer Res; 2021 Apr; 41(4):2059-2065. PubMed ID: 33813414
[TBL] [Abstract][Full Text] [Related]
19. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
20. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
